Moptim announced that the company received U.S. Food and Drug Administration (“FDA”) approval of DEA (Dry Eye Analyzer).
The DEA Dry Eye Analyzer provides the most cost-effective dry eye solutions on the market. It is designed to perform complete examinations for dry eye with outstanding imaging capability, giving optometry the ideal tool to categorize the underlying pathology and severity of the condition. The compact design makes it easy to be integrated into variety of clinical environments. It can be mounted on a slit lamp and easily integrated into an examination, making it easier to add dry eye care to any practice.
The DEA has already been awarded a CE mark and also has sales permits in South America, Africa and other regions. Moptim is strengthening its marketing and sales efforts by adding commercialization partners in the US, where it is now available for sale.
For further information, visit http://www.moptim.com/pro_view-18.html
Moptim is a global medical technology innovator committed to introducing high technology and ophthalmic product solution at a reasonable cost. Moptim offers a wide range of products in three categories: Diagnostics, Refraction, and Surgical. In 2018, Moptim started to expend its overseas market and opened a European office in Athens. Today, Moptim has a strong customer base, providing high-quality products and services to users in more than 50 countries worldwide.